With the rapid pace of M&A happening in the biotechnology sector, Julian Baker and Felix Baker's Baker Bros. Advisors is making a habit of hitting home runs in 2015.
Keep Reading →
July 10 - Hedge Funds, News
Alexion Pharmaceuticals, Inc.
Keep Reading →
June 30 - Hedge Funds, News
We have compared billionaire James Dinan’s York Capital Management’s most recent 13F to the fund’s previous filings (see a history of Dinan's trading activity) and here ...
Keep Reading →
November 15 - Hedge Funds, News
Orphan drugs, those treating rare conditions for small segments of the population, do not normally get much attention compared with the likes of a $12.9 billion Lipitor -- but...
Keep Reading →
October 11 - Hedge Funds, News
Biotechnology stocks often trade with excessive valuations, until one day, large losses occur.
Keep Reading →
September 16 - News
NPS Pharmaceuticals, Inc.
Keep Reading →
September 11 - News
A company with a modus operandi of tackling rare and very rare diseases might not necessarily jump out as a great investment, but this company has banked more than a billion...
Keep Reading →
September 9 - News
If you were to ask many investors, hedge funds are viewed as delayed, outdated investment vehicles of an era lost to time.
Keep Reading →
August 29 - News
In the 21st century investor’s toolkit, there are tons of metrics market participants can use to track the equity markets.
Keep Reading →
August 26 - News
In the 21st century investor’s toolkit, there are dozens of indicators investors can use to analyze Mr. Market.
Keep Reading →
August 26 - News
To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the most innovative are hedge fund and insider trading activity.
Keep Reading →
August 25 - News
To many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age.
Keep Reading →
August 23 - News
To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.
Keep Reading →
August 22 - News
At some point, a company reaches a level of maximum valuation. It doesn't mean the company becomes bad, but rather all upside is priced in and future gains are limited.
Keep Reading →
August 22 - News
If you were to ask many investors, hedge funds are seen as delayed, old financial vehicles of an era lost to time.
Keep Reading →
August 21 - News
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Keep Reading →
August 19 - News
When a company is acquired, the acquirer pays a large premium to where the acquired company’s stock price had previously been trading.
Keep Reading →
August 13 - News
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), already quite expensive, spiked higher since takeover rumors surfaced in early July.
Keep Reading →
August 6 - News
In 2013, a number of new drugs got approvals from the FDA. This provided a boost to the biotech industry as a whole.
Keep Reading →
August 5 - News
In the last couple of months, we saw two big offers being made - and rejected - in the biotech sector.
Keep Reading →
August 5 - News
With the SPDR S&P Biotech Index up 43% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
August 5 - News
There are few times when your doctor or physician will utter the phrase, "I don't know" to a patient, but when you're dealing with the rarest of diseases, then all bets are off...
Keep Reading →
August 5 - News
Three of the biggest names in biotechnology have reported earnings, and their quarters involved very important drug-related information for investors.
Keep Reading →
July 29 - News
The biotech industry is known for fast paced acquisitions and rapid market consolidation.
Keep Reading →
July 29 - News
You may or may not have heard, but it's earnings season again.
Keep Reading →
July 22 - News
In most cases, a biopharmaceutical company chooses to develop either high-priced orphan-designated drugs, or therapeutics to treat large patient populations. Yet one company ...
Keep Reading →
July 19 - News
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
July 18 - News
Chances are that a few biotech companies will be scooped up by larger players over the coming months.
Keep Reading →
July 17 - News
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has a particularly fascinating history, having been at the center of controversy for the better part of its existence. For several ...
Keep Reading →
July 17 - News
Celldex Therapeutics, Inc. (NASDAQ:CLDX), the first antibody-based immunotherapy company, has been a strong buy recommended by several analysts for some time now.
Keep Reading →
July 17 - News
According to a Bloomberg report, Roche is prepared to offer $130 a share to purchase Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Keep Reading →
July 15 - News
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Keep Reading →
July 15 - News
With the SPDR S&P Biotech Index up 33% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
July 15 - News
Imagine finding out that you have a disease that only a handful of people around the world have. Kirstie and Catherine Fields don't have to imagine it.
Keep Reading →
July 5 - News
Love it or hate it, the Patient Protection and Affordable Care Act -- commonly referred to as Obamacare -- changes the health care landscape.
Keep Reading →
July 5 - News
The prescription-drug market currently generates a whopping $950 billion in annual sales, and that figure is likely to grow to $1.2 trillion by 2016.
Keep Reading →
July 3 - News
The word “Orphan’ in biotechnology creates excitement! It means that a company has more years of exclusivity on a product and it also indicates that a company’s technology...
Keep Reading →
June 28 - News
Under normal circumstances, the markets would sell off on news that the U.S. Commerce Department made a downward revision to its final first-quarter GDP growth figure.
Keep Reading →
June 26 - News
Which biotech companies are the best-run? That could be a difficult question to answer, since there are many perspectives on what constitutes a well-run company.
Keep Reading →
June 24 - News
The healthcare industry is slowly becoming what the pre-crash technology industry was of the early 2000's.
Keep Reading →
June 18 - News
"Making every patient count" is a catchy phrase that is perhaps most meaningful for biotech companies like NPS Pharmaceuticals, Inc.
Keep Reading →
June 4 - News
The United States is a wealthy nation when compared to the rest of the world.
Keep Reading →
June 3 - News
Aegerion Pharmaceuticals, Inc.
Keep Reading →
May 31 - News
Having heard about and invested enough in large-cap pharma, I believe it is time to consider funding smaller firms in the sector.
Keep Reading →
May 30 - News
A recent report by EvaluatePharma claims that sales of orphan drugs -- ones that target rare diseases -- will grow at twice the rate of the overall prescription market.
Keep Reading →
May 30 - News
Is Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) going to take off soon? The best stock pickers are taking an optimistic view.
Keep Reading →
May 29 - News
Celgene Corporation (NASDAQ:CELG) was in 44 hedge funds' portfolio at the end of the first quarter of 2013.
Keep Reading →
May 24 - News
To the average investor, there are a multitude of indicators market participants can use to watch stocks.
Keep Reading →
May 23 - News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) peaked on May 14 with a price of $283.99, and has since pulled back to its current price of $260.
Keep Reading →
May 23 - News
Many believed that Q1 earnings would be the start of a larger trend higher that reversed the losses seen in shares of Questcor Pharmaceuticals, Inc.
Keep Reading →
May 3 - News
